Search Result

Results for "

Eltrombopag

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (9) ASK1 (1) Autophagy (1) Bacterial (6) CDK (2) COX (1) ERK (2) Isotope-Labeled Compounds (1) JNK (1) MMP (1) NF-κB (1) PI3K (2) Reference Standards (2) SOD (1) STAT (2) Thrombopoietin Receptor (9) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (9) Endocrinology (1) Infection (6) Inflammation/Immunology (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15306

*Eltrombopag* Maximum Cited Publications 17 Publications Verification SB-497115	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-15306S

Eltrombopag-13C4 1 Publications Verification SB-497115-¹³C₄	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-15306A

Eltrombopag Olamine Maximum Cited Publications 17 Publications Verification Eltrombopag diethanolamine salt; SB-497115GR	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-N1508

Ecliptasaponin A	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .

HY-122620

Rafutrombopag (tautomerism) Hetrombopag (tautomerism); SHR-8735 (tautomerism)	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

HY-15306AR

Eltrombopag Olamine (Standard) Eltrombopag diethanolamine salt (Standard); SB-497115GR (Standard)	Reference Standards Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Olamine) (Standard) is the analytical standard of Eltrombopag (Olamine). This product is intended for research and analytical applications. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-153239

Eltrombopag methyl ester	Thrombopoietin Receptor	Inflammation/Immunology
Eltrombopag methyl ester is a derivative of Eltrombopag, which is a thrombopoietin (Tpo) receptor agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia .

HY-15306R

Eltrombopag (Standard) SB-497115 (Standard)	Reference Standards Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Standard) is the analytical standard of Eltrombopag. This product is intended for research and analytical applications. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-W713365

Eltrombopag-d3 SB-497115-d₃	Isotope-Labeled Compounds Thrombopoietin Receptor Apoptosis Bacterial	Infection Cardiovascular Disease Cancer
Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-145589

Rafutrombopag Hetrombopag; SHR-8735	Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK	Cardiovascular Disease Inflammation/Immunology
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1508

Ecliptasaponin A	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .

Cat. No.	Product Name	Chemical Structure

HY-15306S

Eltrombopag-13C4 1 Publications Verification
Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

Eltrombopag-13C4

1 Publications Verification

Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-W713365

Eltrombopag-d3
Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

Eltrombopag-d3

Eltrombopag-d₃ (SB-497115-d₃) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks